Does Biosilicon deliver? Uni of Pittsburgh to investigate
Friday, 21 May, 2004
Nanotechnology company pSivida's (ASX: PSD) UK subsidiary pSiMedica has signed a collaborative agreement with the University of Pittsburgh to evaluate the use of BioSilicon as a delivery platform for the university's proprietary DNA vaccine technology.
The company will work with the laboratory of Prof Ted Ross, which has experience in developing DNA vaccines for viral diseases to build on prior work performed by pSiMedica on the loading into and release of DNA from BioSilicon matrices to effectively produce the immunogen carried by the DNA sequence.
pSivida managing director Gavin Rezos said the agreement demonstrated the increasing profile of pSivida and pSiMedica in the US.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
